SOUTH SAN FRANCISCO, Calif., Aug. 27 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, today announced that Jerry McMahon, Ph.D., chairman and CEO, will present at two upcoming conferences in early September:
The Thomas Weisel Partners Healthcare Conference 2007 on Wednesday, September 5, at 4:25 p.m. Eastern time at the Four Seasons Hotel in Boston.
BioCentury's "Newsmakers in the Biotech Industry" conference on Thursday, September 6, at 4:00 p.m. Eastern time at the Millennium Broadway Hotel in New York.
Dr. McMahon will provide a corporate overview, including an update on the clinical development program for picoplatin, the Company's lead product candidate.
A live audio webcast of each presentation will be available on the "Events" page of the "News & Events" section of the Company's website at http://www.poniard.com.
About Poniard Pharmaceuticals
Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of innovative oncology products to impact the lives of people with cancer. Picoplatin, the Company's lead product candidate, is a new generation platinum therapy with an improved safety profile. Picoplatin is designed to overcome and prevent platinum resistance associated with chemotherapy in solid tumors. Intravenous picoplatin is currently being studied in clinical trials for the treatment of small cell lung, colorectal and hormone-refractory prostate cancer, and oral picoplatin is in a clinical trial in solid tumors. As part of the Company's strategic goal of building a diverse oncology pipeline, the Company is collaborating with The Scripps Research Institute on the discovery of novel, small-molecule, multi-targeted protein kinase inhibitors. For additional information please visit http://www.poniard.com.
(C) 2007 Poniard Pharmaceuticals, Inc. All Rights Reserved.
Poniard and Poniard Pharmaceuticals are trademarks of Poniard Pharmaceuticals, Inc.
|SOURCE Poniard Pharmaceuticals, Inc.|
Copyright©2007 PR Newswire.
All rights reserved